SAGE THERAPEUTICS INC (SAGE) Stock Price, Forecast & Analysis
USA - NASDAQ:SAGE - US78667J1088 - Common Stock
SAGE Key Statistics, Chart & Performance
The current stock price of SAGE is 8.68 USD. In the past month the price decreased by -4.41%. In the past year, price decreased by -9.58%.
SAGE Latest News, Press Relases and Analysis
SAGE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.14 | 386.36B | ||
| AMGN | AMGEN INC | 14.8 | 174.25B | ||
| GILD | GILEAD SCIENCES INC | 14.43 | 146.60B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.26 | 107.99B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.55 | 69.40B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 866.08 | 57.90B | ||
| INSM | INSMED INC | N/A | 40.57B | ||
| NTRA | NATERA INC | N/A | 28.36B | ||
| BIIB | BIOGEN INC | 9.33 | 22.91B | ||
| INCY | INCYTE CORP | 16.51 | 20.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.2 | 20.53B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 35.89 | 14.88B |
Related stock screener links
About SAGE
Company Profile
SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in providing solutions to brain health medicines. The company is headquartered in Cambridge, Massachusetts and currently employs 353 full-time employees. The company went IPO on 2014-07-18. The firm has developed two FDA-approved treatments indicated for postpartum depression (PPD) and is advancing a portfolio of internally discovered novel chemical entities with the potential to become differentiated treatments designed to improve brain health by primarily targeting two critical central nervous system, receptor systems, GABA and NMDA. Its product ZURZUVAE is for the treatment of PPD in adults. ZURZUVAE is a neuroactive steroid that is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, and is the first oral, once-daily, 14-day treatment specifically indicated for adults with PPD. The company is also evaluating potential indications for SAGE-324, a novel GABAA receptor positive allosteric modulator intended for chronic oral dosing, including seizures in developmental and epileptic encephalopathies. Its other areas of focus are SAGE-319, SAGE-039, and SAGE-817.
Company Info
SAGE THERAPEUTICS INC
55 Cambridge Parkway
Cambridge MASSACHUSETTS 02142 US
CEO: Barry E. Greene
Employees: 353
Phone: 16172998380
SAGE THERAPEUTICS INC / SAGE FAQ
Can you describe the business of SAGE THERAPEUTICS INC?
SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in providing solutions to brain health medicines. The company is headquartered in Cambridge, Massachusetts and currently employs 353 full-time employees. The company went IPO on 2014-07-18. The firm has developed two FDA-approved treatments indicated for postpartum depression (PPD) and is advancing a portfolio of internally discovered novel chemical entities with the potential to become differentiated treatments designed to improve brain health by primarily targeting two critical central nervous system, receptor systems, GABA and NMDA. Its product ZURZUVAE is for the treatment of PPD in adults. ZURZUVAE is a neuroactive steroid that is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, and is the first oral, once-daily, 14-day treatment specifically indicated for adults with PPD. The company is also evaluating potential indications for SAGE-324, a novel GABAA receptor positive allosteric modulator intended for chronic oral dosing, including seizures in developmental and epileptic encephalopathies. Its other areas of focus are SAGE-319, SAGE-039, and SAGE-817.
Can you provide the latest stock price for SAGE THERAPEUTICS INC?
The current stock price of SAGE is 8.68 USD. The price decreased by -0.23% in the last trading session.
What is the dividend status of SAGE THERAPEUTICS INC?
SAGE does not pay a dividend.
How is the ChartMill rating for SAGE THERAPEUTICS INC?
SAGE has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the sector and industry classification for SAGE THERAPEUTICS INC?
SAGE THERAPEUTICS INC (SAGE) operates in the Health Care sector and the Biotechnology industry.
Can you provide the growth outlook for SAGE THERAPEUTICS INC?
The Revenue of SAGE THERAPEUTICS INC (SAGE) is expected to grow by 93.34% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the number of employees for SAGE THERAPEUTICS INC?
SAGE THERAPEUTICS INC (SAGE) currently has 353 employees.
SAGE Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to SAGE. When comparing the yearly performance of all stocks, SAGE turns out to be only a medium performer in the overall market: it outperformed 50.53% of all stocks.
SAGE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SAGE. The financial health of SAGE is average, but there are quite some concerns on its profitability.
SAGE Financial Highlights
Over the last trailing twelve months SAGE reported a non-GAAP Earnings per Share(EPS) of -4.89. The EPS increased by 43.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -71.22% | ||
| ROE | -81.68% | ||
| Debt/Equity | 0 |
SAGE Forecast & Estimates
17 analysts have analysed SAGE and the average price target is 8.67 USD. This implies a price decrease of -0.09% is expected in the next year compared to the current price of 8.68.
For the next year, analysts expect an EPS growth of 44.26% and a revenue growth 93.34% for SAGE